Lexaria Bioscience (LEXX) Total Non-Current Liabilities (2011 - 2023)
Lexaria Bioscience (LEXX) posted Total Non-Current Liabilities of $142587.0 for Q2 2023, up 1826.59% sequentially from $7401.0 in Q3 2022, and up 677.51% YoY from $18339.0 in Q2 2022.
Lexaria Bioscience (LEXX) Total Non-Current Liabilities (2011 - 2023) Analysis & Trends
Lexaria Bioscience has reported Total Non-Current Liabilities for 8 years, with the latest figure at $142587.0 in Q2 2023.
- Quarterly Total Non-Current Liabilities rose 677.51% year-over-year to $142587.0 in Q2 2023, while the trailing twelve-month figure through May 2023 was $142587.0 (up 677.51% YoY) and the FY2022 annual result came in at $7401.0, down 85.19% from the prior year.
- Total Non-Current Liabilities advanced to $142587.0 in Q2 2023 per LEXX's latest filing, from $7401.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $142587.0 in Q2 2023 and troughed at $7401.0 in Q3 2022.
- A 4-year average of $61544.1 and a median of $49989.0 in 2021 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities slumped 85.19% in 2022, then jumped 677.51% in 2023.
- Over 4 years, Total Non-Current Liabilities stood at $110821.0 in 2020, then sank by 64.24% to $39629.0 in 2021, then sank by 81.32% to $7401.0 in 2022, then jumped by 1826.59% to $142587.0 in 2023.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $142587.0, $7401.0, and $18339.0 for Q2 2023, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2023 | 142,587.00 |
| Aug 31, 2022 | 7,401.00 |
| May 31, 2022 | 18,339.00 |
| Feb 28, 2022 | 29,080.00 |
| Nov 30, 2021 | 39,629.00 |
| Aug 31, 2021 | 49,989.00 |
| May 31, 2021 | 60,164.00 |
| Feb 28, 2021 | 70,156.00 |
| Nov 30, 2020 | 110,821.00 |
| Aug 31, 2020 | 120,063.00 |
| May 31, 2020 | 28,756.00 |
| Jul 31, 2014 | 957,418.00 |
| Apr 30, 2014 | 1.05 Mn |
| Jan 31, 2014 | 1.47 Mn |
| Oct 31, 2013 | 1.42 Mn |
| Jul 31, 2013 | 1.40 Mn |
| Apr 30, 2013 | 1.48 Mn |
| Jan 31, 2013 | 1.55 Mn |
| Oct 31, 2012 | 1.71 Mn |
| Oct 31, 2011 | 1.68 Mn |